Assuming the trials yield results, I imagine some formal licensing deals will be struck afterwards between the companies, if one of them doesn't outright acquire VRUS. Whether licensing a deal or an outright takeover Pharmasset will play large pharma against one another and achieve incredible terms for shareholders.